Biocon to merge biologics unit in $5.5 billion deal

NEW DELHI: Biocon volition afloat integrate its biosimilars arm, Biocon Biologics into the parent, successful a woody valuing the portion astatine $5.5 billion.The determination is aimed astatine creating a unified biopharma powerhouse, and to fortify its planetary presumption to pb successful diabetes, oncology, and immunology — therapeutic areas that unneurotic relationship for astir 40% of planetary pharma revenues, Kiran Mazumdar-Shaw, enforcement chairperson, Biocon said connected Saturday.Biocon volition get the remaining involvement successful Biocon Biologics from Serum Institute Life Sciences (Serum), Tata Capital and Activ Pine done a stock swap of 70.28 Biocon shares for each 100 Biocon Biologics shares, astatine a terms of Rs 405.78 per Biocon share.Further, Biocon volition get the residual involvement held by Mylan (Viatris) for $815 million, divided betwixt $400 cardinal successful currency and $415 cardinal done a stock swap of 61.7 Biocon shares for each 100 Biocon Biologics shares astatine a terms of Rs 405.78 per Biocon share.“The combined entity volition connection a unsocial portfolio spanning biosimilars, insulins, GLP-1 peptides and analyzable generics, positioning Biocon among the fewer planetary players with standard successful some generics and biologics. Further, we volition harvester the synergies successful oncology and immunology with the products, successful biosimilars and generics,” said Mazumdar-Shaw.As the lone institution operating globally with some biosimilar insulins and generic versions of analyzable peptides, including GLP-1s, Biocon is poised to code the rapidly expanding ‘diabesity’ market, according to a institution statement.

The company’s committee besides approved raising further capital, of up to Rs 4,500 crore ($500 million) done Qualified Institutional Placement (QIP), taxable to shareholder approval. The proceeds of the QIP volition beryllium mostly utilised towards the currency constituent payable to Viatris.After the transaction and planned fundraise, the promoters’ involvement successful Biocon is expected to driblet to astir 44.4%.Biocon Biologics main enforcement Shreehas Tambe volition go CEO and managing manager of the combined entity post-integration, and Kedar Upadhye volition beryllium the main fiscal officer.

Biocon CEO Siddharth Mittal volition modulation to a radical enactment role, the connection added. The swap ratios person been approved by the committee based connected autarkic valuations by EY.Explaining the move, Mazumdar-Shaw said, “We had created Biocon Biologics arsenic a abstracted entity to pull investments and for a strategical planetary absorption connected biosimilars. Over the years, we did that successfully, adjacent acquiring Viatris’ biosimilars concern for $3 billion. But markets kept devaluing some Biocon and Biocon Biologics due to the fact that of indebtedness overhang and holding institution discount. Now the committee feels it’s a amended determination to enactment unneurotic and consolidate, arsenic it gives america a overmuch stronger equilibrium sheet.

”